![]() Codiak Biosciences Codiak Biosciences is a biopharmaceutical company focused on the development of exosome-based therapeutics. | ![]() Nimbus Therapeutics Nimbus Therapeutics is a biotechnology company which operates an application of computational chemistry to design treatments for substantial and underserved human diseases. | ![]() Takeda Takeda Pharmaceutical (武田薬品工業株式会社) is a biopharmaceutical company engaged in the research, development, production, and commercialization of pharmaceutical products. | ![]() AstraZeneca AstraZeneca is a biopharmaceutical company specializing in the discovery, development, manufacturing, and marketing of prescription medicines. | ![]() ArunA Bio ArunA Bio is engaged in advancing a new class of cell-free biologics, exosomes, for the treatment of central nervous system (CNS) and neurodegenerative disorders and leveraging a platform to optimize the delivery of RNAs, antibodies, genes and small molecules. | ![]() Evox Therapeutics Evox Therapeutics is a biotechnology company developing exosome-based gene editing therapies. | |
Founding Date | Founding Date 2015 | Founding Date 2009 | Founding Date 1781 | Founding Date 1999 | Founding Date 2003 | Founding Date 2016 |
Type | Type Public | Type Private | Type Public | Type Public | Type Private | Type Subsidiary |
Tags | ||||||
Locations | Locations Cambridge, US HQ | Locations Cambridge, US HQ | Locations Cambridge, GB HQ Alger, DZ Buenos Aires, AR Macquarie Park, AU Macquarie Park, AU North Ryde, AU Wien, AT see more | Locations Athens, US HQ Athens, US | Locations Oxford, GB HQ | |
Employees | Employees 992% decrease | Employees 1091% increase | Employees 47,4554% decrease | Employees 94,300 | Employees 274% increase | Employees 452% decrease |
Valuation ($) | Valuation ($) 2.8 m | Valuation ($) N/A | Valuation ($) 43.7 b | Valuation ($) 2.7 b | Valuation ($) N/A | Valuation ($) N/A |
Financial | ||||||
Revenue (est.) | Revenue (est.) $22.9m (FY, 2021) | Revenue (est.) N/A | Revenue (est.) ¥4.6t (FY, 2025) | Revenue (est.) $58.7b (FY, 2025) | Revenue (est.) N/A | Revenue (est.) N/A |
Cost of goods | Cost of goods N/A | Cost of goods N/A | Cost of goods ¥818.8b (FY, 2025) | Cost of goods $4.9b (FY, 2025) | Cost of goods N/A | Cost of goods N/A |
Gross profit | Gross profit N/A | Gross profit N/A | Gross profit ¥3.8t (FY, 2025) | Gross profit $54.2b (FY, 2025) | Gross profit N/A | Gross profit N/A |
Net income | Net income ($37.2m) (FY, 2021) | Net income N/A | Net income ¥108.1b (FY, 2025) | Net income $10.2b (FY, 2025) | Net income N/A | Net income N/A |
Operating ⚠ | ||||||
Phase II Trials Products | Phase II Trials Products 2 (Q2, 2020) | Phase II Trials Products N/A | Phase II Trials Products 10 (May, 2025) | Phase II Trials Products N/A | Phase II Trials Products N/A | Phase II Trials Products N/A |
Funding | ||||||
Latest funding round | Latest funding round N/A | Latest funding round $ 105m (almost 5 years ago) | Latest funding round N/A | Latest funding round N/A | Latest funding round $ 4.5m (over 6 years ago) | Latest funding round N/A |
Total funding raised | Total funding raised $ 168.5m | Total funding raised $ 242m | Total funding raised $ 57.8m | Total funding raised $ 1b | Total funding raised $ 26.9m | Total funding raised $ 158.6m |

Nimbus Therapeutics is a biotechnology company which operates an application of computational chemistry to design treatments for substantial and underserved human diseases.
View company
Takeda Pharmaceutical (武田薬品工業株式会社) is a biopharmaceutical company engaged in the research, development, production, and commercialization of pharmaceutical products.
View company
AstraZeneca is a biopharmaceutical company specializing in the discovery, development, manufacturing, and marketing of prescription medicines.
View company
ArunA Bio is engaged in advancing a new class of cell-free biologics, exosomes, for the treatment of central nervous system (CNS) and neurodegenerative disorders and leveraging a platform to optimize the delivery of RNAs, antibodies, genes and small molecules.
View company